Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, will be attending the 2018 BIO International Convention (“BIO International”) this week in Boston, Massachusetts. BIO International is the largest biopharma partnering event of the year, attracting over 16,000 leaders and business development executives from 5,000 companies across the globe.

“The recent successful Phase 2B GI safety study for our lead drug, ATB-346, has provided unequivocal validation of our hydrogen sulfide technology and has strengthened our position in partnering discussions,” commented Dan Legault, Antibe’s CEO. “We are now engaging multinational pharmaceutical firms with an objective of securing strategic licensing deals for the major markets. In parallel, we continue to advance on-going discussions for smaller market opportunities in our efforts to fully monetize ATB-346 for shareholders.”

Antibe will be engaging in several days of one-on-one meetings with pharmaceutical companies to discuss licensing opportunities for ATB-346 and its hydrogen sulfide platform. Although Antibe is in active discussions with several parties, there can be no assurance that any partnering discussions will materialize into a successful transaction.

About BIO International
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists and biopharma leaders. The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition - the BIO Exhibition.

About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.


Antibe Therapeutics Inc.
Dan Legault, 416-473 4095
Chief Executive Officer

Source: Antibe Therapeutics Inc.

Back to news